Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (41-50 of 277) with videos related to

Pageof 28
Sort By:
Oncoscience|August 8, 2017
Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscapeIshwaria M Subbiah, Apostolia Tsimberidou, Vivek Subbiah, et al.
World Neurosurgery|August 14, 2016
Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus CallosumSarah T Garber, Laith Khoury, Diana Bell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2012
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009Filip Janku, Donald A Berry, Jing Gong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatmentGerald S Falchook, Filip Janku, Anne S Tsao, et al.
NPJ Precision Oncology|September 29, 2023
ALK fusions in the pan-cancer setting: another tumor-agnostic target?Aditya Shreenivas, Filip Janku, Mohamed A Gouda, et al.
Oncotarget|January 8, 2014
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphomaVivek Subbiah, Robert E Brown, Mary F McGuire, et al.
Oncology|December 17, 2013
Retreatment after secondary resistance or mixed response: a pilot studyAung Naing, Rishi Agarwal, Gerald Falchook, et al.
Endocrine|February 13, 2022
Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancerMohamed A Gouda, Emily Ong, Helen J Huang, et al.
Journal of Cancer|April 15, 2020
RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patientsQian Li, Helen J Huang, Jing Ma, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 30, 2013
A pilot study of temsirolimus and body compositionHeloisa Veasey-Rodrigues, Henrique A Parsons, Filip Janku, et al.
Pageof 28

Showing results (41-50 of 277) with videos related to

Sort By:
Pageof 28
Oncoscience|August 8, 2017
Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscapeIshwaria M Subbiah, Apostolia Tsimberidou, Vivek Subbiah, et al.
World Neurosurgery|August 14, 2016
Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus CallosumSarah T Garber, Laith Khoury, Diana Bell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2012
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009Filip Janku, Donald A Berry, Jing Gong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatmentGerald S Falchook, Filip Janku, Anne S Tsao, et al.
NPJ Precision Oncology|September 29, 2023
ALK fusions in the pan-cancer setting: another tumor-agnostic target?Aditya Shreenivas, Filip Janku, Mohamed A Gouda, et al.
Oncotarget|January 8, 2014
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphomaVivek Subbiah, Robert E Brown, Mary F McGuire, et al.
Oncology|December 17, 2013
Retreatment after secondary resistance or mixed response: a pilot studyAung Naing, Rishi Agarwal, Gerald Falchook, et al.
Endocrine|February 13, 2022
Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancerMohamed A Gouda, Emily Ong, Helen J Huang, et al.
Journal of Cancer|April 15, 2020
RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patientsQian Li, Helen J Huang, Jing Ma, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 30, 2013
A pilot study of temsirolimus and body compositionHeloisa Veasey-Rodrigues, Henrique A Parsons, Filip Janku, et al.
Pageof 28